All Categories
ArteraAI Prostate Test (Post-RP) Added to NCCN Guidelines
The addition builds on Artera’s inclusion in the guidelines for localized prostate cancer, extending decision support to pati [...]
Artera Earns Frost & Sullivan’s 2026 Technology Innovation Leadership...
Recognition highlights Artera's clinical evidence and its role in advancing precision oncology SAN FRANCISCO – October 29, 20 [...]
The next chapter of AI in cancer care isn’t...
There is certainly no shortage of interest in artificial intelligence in oncology. Hundreds of AI approaches are being develo [...]
From Awareness to Authority: How Patients Shaped Precision Medicine
Breast Cancer Awareness Month has evolved far beyond a public-health campaign. Over four decades, patient advocacy, philanthr [...]
New Data Highlight Artera’s MMAI Consistency Across Diverse Patient...
Five abstracts spanning global patient cohorts and U.S. cooperative trials reinforce the prognostic and predictive power of A [...]
Investment Reports Andre Esteva Interview
Artera is a precision medicine company developing artificial intelligence tools to support personalized cancer treatment deci [...]
Rethinking ADT: AI Biomarkers in Intermediate-Risk Prostate Cancer
A recently published cost-effectiveness analysis has found that using the ArteraAI Prostate Test to guide androgen deprivatio [...]
Is Your Pathology AI Really Ready?
AI is advancing rapidly in pathology, with new FDA clearances, reimbursement pathways, and growing adoption across health sys [...]